In 2021, the average mortality rate across OECD countries from preventable causes stood at 158 deaths per 100,000 population. This varied widely from just 83 deaths in Israel to 435 preventable deaths in Mexico per 100,000 population. The OECD defines preventable mortality as causes of death amongst people aged under 75 years that can be mainly avoided through effective public health and primary prevention interventions (i.e. before the onset of disease/injury, to reduce incidence). Treatable (or amenable mortality is defined as causes of death that can be mainly avoided through timely and effective health care interventions including secondary prevention and treatment (i.e. after the onset of disease, to reduce case fatality). This statistic presents the mortality rates from preventable causes worldwide in 2021, by country.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

In 2022, the states with the highest death rates due to heart disease were Oklahoma, Mississippi, and Alabama. That year, there were around 257 deaths due to heart disease per 100,000 population in the state of Oklahoma. In comparison, the overall death rate from heart disease in the United States was 167 per 100,000 population. The leading cause of death in the United States Heart disease is the leading cause of death in the United States, accounting for 21 percent of all deaths in 2022. That year, cancer was the second leading cause of death, followed by unintentional injuries and COVID-19. In the United States, a person has a one in six chance of dying from heart disease. Death rates for heart disease are higher among men than women, but both have seen steady decreases in heart disease death rates since the 1950s. What are risk factors for heart disease? Although heart disease is the leading cause of death in the United States, the risk of heart disease can be decreased by avoiding known risk factors. Some of the leading preventable risk factors for heart disease include smoking, heavy alcohol use, physical inactivity, an unhealthy diet, and being overweight or obese. It is no surprise that the states with the highest rates of death from heart disease are also the states with the highest rates of heart disease risk factors. For example, Oklahoma, the state with the highest heart disease death rate, is also the state with the third-highest rate of obesity. Furthermore, Mississippi is the state with the highest levels of physical inactivity, and it has the second-highest heart disease death rate in the United States.

As of 2023, the U.S. states with the highest smoking rates included West Virginia, Tennessee, and Louisiana. In West Virginia, around 20 percent of all adults smoked as of this time. The number of smokers in the United States has decreased over the past decades. Who smokes? The smoking rates for both men and women have decreased for many years, but men continue to smoke at higher rates than women. As of 2021, around 13 percent of men were smokers compared to 10 percent of women. Concerning race and ethnicity, smoking is least prevalent among Asians with just five percent of this population smoking compared to 13 percent of non-Hispanic whites. Health impacts of smoking The negative health impacts of smoking are vast. Smoking increases the risk of heart disease, stroke, and many different types of cancers. For example, smoking is estimated to be attributable to 81 percent of all deaths from lung cancer among adults 30 years and older in the United States. Smoking is currently the leading cause of preventable death in the United States.

Between 1970 and 1988, major cardiovascular diseases were the most common cause of death in both the United States and Soviet Union. However, the death rate in the U.S. fell between the given years, whereas the USSR's rate increased significantly, especially during the 1970s. Malignancies (i.e. cancers) were the second most common cause of death, with both death rates rising over time. Other causes that that varied greatly between the two countries were accidents and adverse effects, where the USSR's rate was almost double that of the U.S. in 1980; pulmonary diseases, where the U.S. rate was higher in 1988 despite having been four times lower in 1970; and diabetes, where the U.S. rate was higher by a factor of 11 in 1970 and a factor of four in 1988.

There were, of course, variations between the two countries in their standards of diagnosis and the classification of causes of death, with U.S. records generally thought to be more accurate, whereas the USSR's rates improved with time. The Soviet Union also did not provide separate data for deaths caused by liver disease or pneumonia/influenza, possibly due to the rise and prevalence of alcohol-related deaths during the given period, which the government wished to downplay. Preventable deaths related to alcohol and substance abuse (including tobacco) were major factors in the Soviet Union's high death rates in certain categories, such as accidental deaths, pulmonary disease, and suicides. In contrast, the U.S.' higher rate of diabetes deaths has been attribute to an increase in levels of Type 2 diabetes, which is most-commonly caused by lifestyle and dietary factors.

Tobacco-related deaths remain the leading cause of preventable death in the United States. Veterans suffering from posttraumatic stress disorder (PTSD)—about 11% of those receiving care from the Department of Veterans Affairs (VA)—have triple the risk of developing tobacco use disorder (TUD). The most efficacious strategies being used at the VA for smoking cessation only result in a 23% abstinence rate, and veterans with PTSD only achieve a 4.5% abstinence rate. Therefore, there is a critical need to develop more effective treatments for smoking cessation. Recent studies suggest the insula is integrally involved in the neurocircuitry of TUD. Thus, we propose a feasibility phase II randomized controlled trial (RCT) to study a form of repetitive transcranial magnetic stimulation (rTMS) called intermittent theta burst stimulation (iTBS). iTBS has the advantage of allowing for a patterned form of stimulation delivery that we will administer at 90% of the subject’s resting motor threshold (rMT) applied over a region in the right post-central gyrus most functionally connected to the right posterior insula. We hypothesize that by increasing functional connectivity between the right post-central gyrus and the right posterior insula, withdrawal symptoms and short-term smoking cessation outcomes will improve. Fifty eligible veterans with comorbid TUD and PTSD will be randomly assigned to active-iTBS + cognitive behavioral therapy (CBT) + nicotine replacement therapy (NRT) (n = 25) or sham-iTBS + CBT + NRT (n = 25). The primary outcome, feasibility, will be determined by achieving a recruitment of 50 participants and retention rate of 80%. The success of iTBS will be evaluated through self-reported nicotine use, cravings, withdrawal symptoms, and abstinence following quit date (confirmed by bioverification) along with evaluation for target engagement through neuroimaging changes, specifically connectivity differences between the insula and other regions of interest.

Fall-Related Death Rate - This indicator shows the rate of fall-related deaths per 100,000 population. Falls are a major cause of preventable death among the elderly and have increased across age groups in the past decade. Causes of fall-related deaths differ between the elderly and young and middle-aged populations, and require different prevention strategies. In 2009, falls accounted for 30% of accidental deaths.

Problem:• Opioid overdoses claim a life every 24 minutes in the United States, and five people a day in Massachusetts.1• Not since the AIDS epidemic of the 1980s and 1990s has Massachusetts seen such a sharp increase in a single category of deaths.2• Opioid overdoses are the leading cause of preventable deaths for all Americans under the age of 50.3• On October 26th, 2017, President Trump declared the opioid crisis a Public Health Emergency, failing to fulfill his promise to declare a National Emergency on opioids.4Project Overview:• Illustrate how Massachusetts is impacted by the opioid epidemic, and how it is extending across the state.

• Show the distribution of 'Naloxone Pharmacies' across Massachusetts to identify locations without access.

• Highlight the correlation between crime and opioid overdoses in Cambridge.

• Identify suitable street corners for the installation of naloxone dispensaries, focusing on Cambridge, MA.Data:• Cambridge Police Department’s Crime Analysis Unit and Special Investigation Unit provided addresses reported as suspected opioid overdoses in 2016. • State-wide opioid data were publicly available via Massachusetts Department of Public Health, and through the Chapter 55 legislative report. • The list of pharmacies with standing orders of naloxone was also publicly available via Executive Office of Health & Human Services.

Estimates based on District hospital discharge data. Counts of and rates based on fewer than 10 births are suppressed for privacy reasons.

Source: Center for Policy Planning and Evaluation, DC Department of Health

Why This Matters

In recent decades, pregnancy-related deaths have risen in the United States. Although relatively rare and mostly preventable, the numbers are high relative to other high-income countries.

Leading underlying causes of pregnancy-related deaths include severe bleeding, cardiac and coronary conditions, and infections. Individual, social, and structural factors contribute to maternal death risk and trends, including maternal age, preexisting medical conditions, access to quality care, insurance, and longstanding racial and ethnic inequities.

Maternal mortality rates are disproportionately higher among birthing people who are Black, Indigenous, and people of color.

The District Response

Enhancements to District healthcare programs. Medicaid expansion provides greater access to prenatal care, extended postpartum Medicaid coverage for a full year, and reimbursement for doula services through all District programs. For a list of local and national resources on pregnancy and related topics, click here.

Paid family leave program providing 12 weeks to bond with a new child or care for a serious health condition, and 2 weeks specifically for prenatal care.

The District established the Maternal Mortality Review Committee, which investigates the causes of maternal deaths, and develops strategic frameworks to improve maternal health.

BackgroundWhile the high prevalence of preterm births and its impact on infant mortality in the US have been widely acknowledged, recent data suggest that even full-term births in the US face substantially higher mortality risks compared to European countries with low infant mortality rates. In this paper, we use the most recent birth records in the US to more closely analyze the primary causes underlying mortality rates among full-term births.Methods and findingsLinked birth and death records for the period 2010–2012 were used to identify the state- and cause-specific burden of infant mortality among full-term infants (born at 37–42 weeks of gestation). Multivariable logistic models were used to assess the extent to which state-level differences in full-term infant mortality (FTIM) were attributable to observed differences in maternal and birth characteristics. Random effects models were used to assess the relative contribution of state-level variation to FTIM. Hypothetical mortality outcomes were computed under the assumption that all states could achieve the survival rates of the best-performing states. A total of 10,175,481 infants born full-term in the US between January 1, 2010, and December 31, 2012, were analyzed. FTIM rate (FTIMR) was 2.2 per 1,000 live births overall, and ranged between 1.29 (Connecticut, 95% CI 1.08, 1.53) and 3.77 (Mississippi, 95% CI 3.39, 4.19) at the state level. Zero states reached the rates reported in the 6 low-mortality European countries analyzed (FTIMR < 1.25), and 13 states had FTIMR > 2.75. Sudden unexpected death in infancy (SUDI) accounted for 43% of FTIM; congenital malformations and perinatal conditions accounted for 31% and 11.3% of FTIM, respectively. The largest mortality differentials between states with good and states with poor FTIMR were found for SUDI, with particularly large risk differentials for deaths due to sudden infant death syndrome (SIDS) (odds ratio [OR] 2.52, 95% CI 1.86, 3.42) and suffocation (OR 4.40, 95% CI 3.71, 5.21). Even though these mortality differences were partially explained by state-level differences in maternal education, race, and maternal health, substantial state-level variation in infant mortality remained in fully adjusted models (SIDS OR 1.45, suffocation OR 2.92). The extent to which these state differentials are due to differential antenatal care standards as well as differential access to health services could not be determined due to data limitations. Overall, our estimates suggest that infant mortality could be reduced by 4,003 deaths (95% CI 2,284, 5,587) annually if all states were to achieve the mortality levels of the best-performing state in each cause-of-death category. Key limitations of the analysis are that information on termination rates at the state level was not available, and that causes of deaths may have been coded differentially across states.ConclusionsMore than 7,000 full-term infants die in the US each year. The results presented in this paper suggest that a substantial share of these deaths may be preventable. Potential improvements seem particularly large for SUDI, where very low rates have been achieved in a few states while average mortality rates remain high in most other areas. Given the high mortality burden due to SIDS and suffocation, policy efforts to promote compliance with recommended sleeping arrangements could be an effective first step in this direction.

This project page holds the study materials for a systematic case series of coroners' Prevention of Future Deaths reports involving diagnostic errors.

1: Background A diagnostic error can be characterised as a ‘failure to establish an accurate and timely explanation of a patient’s health problems’ (1). Diagnostic errors present an obvious risk to patient safety – both if an inaccurate and if a late diagnosis is made. If the diagnosis is inaccurate, this leads to harm not only through failure to treat the disease but also through unnecessary medical interventions (1). While a late diagnosis generally leads to worsened patient outcomes due to the progression of the disease state (2), what can be classed as late varies greatly between diseases and settings. For example, septic shock in an urgent hospital can lead to death in 48 hours (3), whereas a 48-hour delay in a cancer diagnosis is unlikely to make much difference to the patient’s prognosis. The progression of the disease state is especially relevant in the treatment of cancers due to their ability to metastasise; 5-year survival rates fall from almost 100% in women diagnosed with stage 1 breast cancer to 25% in those diagnosed with stage 4 breast cancer (3). Diagnostic errors and delays can occur in all healthcare settings. Primary care is a key setting for the detection of diagnostic errors as it is typically the first point of contact with a patient. A longitudinal review of 21 general practices found a missed diagnostic opportunity (MDO) in 4% of the 2057 cases reviewed (4). When a MDO occurred, it was stated that 40% of these missed diagnoses caused moderate to severe harm to patients. The study also found that while the majority (58%) of these happened during GP consultations, other reasons for MDOs included performance/interpretation of a diagnostic test (25%), the failure to follow-up and track diagnostic information (i.e. tests not being performed) in 24% of cases. Issues in referring to a specialist made up another 12% (4). A study reviewing diagnostic errors in an emergency setting defined a diagnostic error as “a diagnosis that could have been made in the Accident and Emergency (A&E) department but that was not made until after the patient left A&E”. The study found that 953 diagnostic errors were noted in 934 patients (5), three of whom later died. It was found that 80% of these were missed fractures, the reasons being either a failure to radiograph (13%) or a misreading of radiographs (78%) (5). The author concluded that most abnormalities missed on the radiographs were not difficult to diagnose and suggested that junior doctors should receive specific training and be tested on their ability to interpret radiographs before being allowed to work unsupervised. The Office for National Statistics (ONS) report on avoidable mortality in 2019 states that out of the 36% of deaths classified as avoidable, roughly 8% of deaths were treatable (could have been avoided through timely and effective healthcare interventions) (6). A retrospective case record review of deaths in 2009 judged that 5.2% of deaths had a 50% or greater chance of being preventable (7). Extrapolation from their data suggests that in 2009, there would have been 11,859 adult preventable deaths in hospitals in England. Prevention of Future Deaths reports (PFDs) are written by coroners in England and Wales to express their concerns if they believe that action should be taken to prevent future deaths. Coroners send PFDs to an organisation, such as a hospital or a governmental regulator, who have a legal duty to respond within 56 days to outline what actions they will take in response to the report. PFDs have been used to assess deaths involving a range of conditions and patient safety concerns, ranging from medicine-related deaths to lessons from the COVID-19 pandemic (8–10).

2: Objectives and aims In this study, we aim to analyse PFDs which mention diagnostic errors to understand the concerns that they raise. A previous study has also used PFDs to analyse diagnostic errors (11), however that study specifically focused on GPs working in/alongside emergency departments whereas this study will cover all specialties. Another difference is that they also used National Reporting and Learning System (NRLS) patient safety incident reports, which we will not do in this study. Our objectives are to discover: 1. PFDs in which diagnostic errors were mentioned as having caused or contributed to the death and the types of diseases mentioned; 2. geographical variations in such PFDs; 3. the types of concerns voiced by coroners and actions recommended by them in diagnostic error-related PFDs; 4. the numbers and types of individuals or organizations to whom the medicines-related PFD reports were addressed; and 5. how many responses were received within the 56-day requirement.

Noncommunicable diseases and mental health conditions (referred to collectively as NMHs) are the greatest cause of preventable death, illness, and disability in South America and negatively affect countries’ economic performance through their detrimental impacts on labor supply and capital investments. Sound, evidence-based policy-making requires a deep understanding of the macroeconomic costs of NMHs and of their distribution across countries and diseases. The paper estimates and projects the macroeconomic burden of NMHs over the period 2020–2050 in 10 South American countries. We estimate the impact of NMHs on gross domestic product (GDP) through a human capital-augmented production function approach, accounting for mortality and morbidity effects of NMHs on labor supply, for the impact of treatment costs on physical capital accumulation, and for variations in human capital by age. Our central estimates suggest that the overall burden of NMHs in these countries amounts to $7.3 trillion (2022 international $, 3% discount rate, 95% confidence interval: $6.8–$7.8 trillion). Overall, the macroeconomic burden of NMHs is around 4% of total GDP over 2020–2050, with little variation across countries (from 3.2% in Peru to 4.5% in Brazil). In other words, without NMHs, annual GDP over 2020–2050 would be about 4% larger. In most countries, the largest macroeconomic burden is associated with cancers. Results from the paper point to a significant macroeconomic burden of NMHs in South America and provide a strong justification for investment in NMH prevention, early detection, treatment, and formal and informal care.

This dataset contains data from WHO's data portal covering the following categories:

Air pollution, Antimicrobial resistance (AMR), Assistive technology, Child mortality, Dementia diagnosis, treatment and care, Dementia policy and legislation, Environment and health, Foodborne Diseases Estimates, Global Dementia Observatory (GDO), Global Health Estimates: Life expectancy and leading causes of death and disability, Global Information System on Alcohol and Health, HIV, Health Inequality Monitor, Health financing, Health systems, Health taxes, Health workforce, Hepatitis, Immunization coverage and vaccine-preventable diseases, International Health Regulations (2005) monitoring framework, Malaria, Maternal and reproductive health, Mental health, Neglected tropical diseases, Noncommunicable diseases, Nutrition, Oral Health, Priority health technologies, Resources for Substance Use Disorders, Road Safety, SDG Target 3.8 | Achieve universal health coverage (UHC), Sexually Transmitted Infections, Tobacco control, Tuberculosis, Vaccine-preventable communicable diseases, Violence against women, Violence prevention, Water, sanitation and hygiene (WASH), Women and health, World Health Statistics.

For links to individual indicator metadata, see resource descriptions.

Maternal mortality rates can vary significantly around the world. For example, in 2022, Estonia had a maternal mortality rate of zero per 100,000 live births, while Mexico reported a rate of 38 deaths per 100,000 live births. However, the regions with the highest number of maternal deaths are Sub-Saharan Africa and Southern Asia, with differences between countries and regions often reflecting inequalities in health care services and access. Most causes of maternal mortality are preventable and treatable with the most common causes including severe bleeding, infections, complications during delivery, high blood pressure during pregnancy, and unsafe abortion. Maternal mortality in the United States In 2022, there were a total of 817 maternal deaths in the United States. Women aged 25 to 39 years accounted for 578 of these deaths, however, rates of maternal mortality are much higher among women aged 40 years and older. In 2022, the rate of maternal mortality among women aged 40 years and older in the U.S. was 87 per 100,000 live births, compared to a rate of 21 among women aged 25 to 39 years. The rate of maternal mortality in the U.S. has risen in recent years among all age groups. Differences in maternal mortality in the U.S. by race/ethnicity Sadly, there are great disparities in maternal mortality in the United States among different races and ethnicities. In 2022, the rate of maternal mortality among non-Hispanic white women was about 19 per 100,000 live births, while non-Hispanic Black women died from maternal causes at a rate of almost 50 per 100,000 live births. Rates of maternal mortality have risen for white and Hispanic women in recent years, but Black women have by far seen the largest increase in maternal mortality. In 2022, around 253 Black women died from maternal causes in the United States.

Per capita cigarette consumption in the United States has decreased in recent years, with smokers in 2015 consuming an average of 1,078 cigarettes per capita. In total, there were around 267 billion cigarettes consumed in the U.S. that year. Cigarette consumption in the U.S. has decreased due to public policies limiting where people can smoke, higher taxes on cigarettes, and increased awareness by the general public of the health risks associated with smoking.

Smokers in the U.S.

Even though cigarette consumption has decreased, there are still around 38 million people in the U.S. who regularly smoke cigarettes. This is around 15.5 percent of the entire population. However, in the year 2000, 23 percent of the population smoked, a significant difference from present day figures. Smoking remains more common among males than females and rates of smoking among adolescents have decreased.

Health risks

Smoking has been proven to increase the risk of a variety of diseases and is the leading cause of preventable death in the U.S. Smoking harms almost every organ in the body and increases a person’s chance of developing lung cancer, heart disease, and stroke. For example, men who smoke are 25 times more likely to develop lung cancer than men who don’t smoke. Furthermore, around 81 percent of all deaths from lung, bronchus and trachea cancer can be attributed to cigarette smoking.

Macroeconomic burden of NMHs over the period 2020–2050.

According to Cognitive Market Research, the Global Pneumococcal Vaccines Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

The Pneumococcal Vaccines market will expand significantly by XX% CAGR between 2024 and 2031.
The Pneumococcal Conjugate vaccine type accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
The usage of the Prevenar13 pneumococcal vaccine holds the largest market share compared to others.
By Distribution channel, the public health agencies hold the largest market share compared to others.
North-America region dominated the market and accounted for the highest revenue of XX% in 2022 and it is projected that it will grow at a CAGR of XX% in the future.

Factors Affecting the Growth of the Pneumococcal Vaccines Market

The rising cases of pneumonia are directly driving the demand for pneumococcal vaccines in the market.

Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae, as called pneumococcus. There are more than 100 subtypes and most of the subtypes can cause disease, but only a few produce the majority of invasive pneumococcal infections. Pneumonia is the single largest infectious cause of death in children worldwide. It causes more than a million hospitalizations and more than 50,000 deaths each year. (Source: https://www.lung.org/lung-health-diseases/lung-disease-lookup/pneumonia/five-facts-you-should-know)

Around 4,000 cases of pneumococcal bacteremia occur every year in the United States. Bacteremia is the most common clinical presentation among children aged two years and younger, accounting for 70% of invasive disease in this group. Additionally, there are an estimated 2,000 cases of pneumococcal meningitis every year. Considering the criticality, pneumococcal disease is a serious disease that causes much sickness and death. Around, 30,300 cases and 3,250 deaths from invasive pneumococcal diseases are estimated to have occurred in the United States in 2019. (Source: https://www.immunize.org/wp-content/uploads/catg.d/p4213.pdf)

Furthermore, pneumonia accounts for around 14% of all deaths of children under 5 years old, killing nearly 740,180 children in 2019. (Source: https://www.who.int/news-room/fact-sheets/detail/pneumonia)

Certain medical concerns associated with the pneumococcal vaccine may restrict the Pneumococcal Vaccines Market growth.

Normally, most people who get a pneumococcal vaccine do not have any serious problems with it; however, with any medicines and vaccines, chances of being caught to certain side effects are always there. The side effects tend to be mild and go away on their own within a few days; however, some serious reactions might be possible.

Mild problems related to PCV15, PCV20, or PPSV23 can include Redness, swelling, pain, or tenderness where the shot was given, Fever or chills, Loss of appetite, Fussiness, Feeling tired, Headache, Muscle ache, or joint pain. These symptoms may lead people to avoid the vaccination, resulting in the restriction in the market growth. (Source: https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html)

The most common side effects from pneumococcal vaccines are mild and last for 1 or 2 days. The chances of getting severe allergic reactions are very rare.; however, such independent risk factors can restrict the market growth for pneumococcal vaccines.

An innovative financial mechanism by the Pneumococcal Advance Market Commitment can be considered as an opportunity for vaccine makers to produce vaccines at affordable prices.

Each year, pneumococcal disease takes the lives of half a million children under five years of age, making it the leading vaccine-preventable cause of death among young children. The most effective estimate to prevent these deaths is to ensure access to effective, safe, and affordable vaccines. To make this happen, a pneumococcal Advance Market Commitment (AMC) has been designed to protect children against pneumococcal disease.

This financial commitment offers an innovative funding mechanism with the help of donor commitments, that can benefit vaccine makers to produce suitable and affordable vaccines for the world’s poorest countries accelerating the global roll-out of a vaccine against the world’s leading cause of c...

In 2021, there were over ** million deaths from all types of cardiovascular diseases all over the world. This statistic describes the number of deaths caused by selected chronic diseases worldwide in 2021. Chronic disease has widespread consequences on both individuals, impacting both quality and length of life, as well as on societies and governments worldwide. Chronic disease The burden of chronic diseases, which is made up of the resulting disabilities and deaths, is increasing all over the globe. In 2022, lung cancer caused over *** million deaths worldwide, accounting for the highest number of cancer deaths. Furthermore, it is estimated that by 2045, there will be *** million people living with diabetes all over the globe. Although chronic diseases are not curable, their risk factors are highly preventable, usually through individual lifestyle and behavioral modifications. Public policies have been put into place in many countries worldwide to promote healthier lifestyles, for example by limiting the consumption of tobacco and alcohol. Impact on societies Chronic diseases can result in a heavy economic burden due to related health care costs and through the loss of workforce. Countries of all income statuses are affected by chronic diseases, with the leading causes of death in high-income countries from chronic disease. Moreover, the rising impact of chronic disease in low-income countries leads to a double burden, as they are forced to deal with both infectious diseases and non-communicable diseases. Weak health systems and poor economies often pose limits to these countries’ abilities to cope as well.

Snapshot img

Venturi Mask Market Size 2024-2028

The venturi mask market size is forecast to increase by USD 2.74 billion at a CAGR of 15.63% between 2023 and 2028.

The market is experiencing significant growth due to the increasing prevalence of chronic respiratory disorders, such as asthma and COPD. This trend is driven by the rising number of people suffering from these conditions and the subsequent demand for effective respiratory treatment solutions. Additionally, there is a growing focus on improved product designs for medical devices to enhance patient comfort and compliance, while healthcare services continue to prioritize innovation and patient-centered care. However, unfavorable reimbursement scenarios pose a challenge to market growth. Despite this, advancements in technology and the development of innovative mask designs offer opportunities for market expansion. The market is expected to grow steadily due to the high prevalence of chronic respiratory disorders and the availability of advanced healthcare facilities. Companies in this market are investing in research and development to create masks with superior features, such as improved fit, ease of use, and enhanced filtration capabilities. 

What will be the Size of the Venturi Mask Market During the Forecast Period?

Request Free Sample

The market, a segment of the global air pollution mitigation industry, is experiencing significant growth due to the rising prevalence of air pollution-related health issues, including preventable deaths from COPD and cardiovascular diseases. This trend is particularly prominent In the sports and geriatric populations, as physical activity and aging can exacerbate respiratory conditions. Cigarette smoke is another major contributor to air pollution and associated health risks, further driving demand for Venturi masks.
The homecare segment of the market is expected to dominate, driven by increasing healthcare costs and the growing elderly population. Economic, social, and political factors, including GDP growth rate, demographic shifts, and regulations, are influencing market dynamics. Quantitative data indicates a steady increase in market size, while qualitative data from subject-related experts advises on pricing trends and product lifecycle stages. Positive changes in regulations and public awareness of air pollution's health impacts are also contributing to market growth.

How is this Venturi Mask Industry segmented and which is the largest segment?

The venturi mask industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Application

  COPD
  Asthma
  Others


End-user

  Hospitals and clinics
  Homecare
  ASCs


Product Type

  Adult Venturi Masks
  Pediatric Venturi Masks
  Disposable Adjustable Venturi Masks


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Asia

    China
    India
    Japan


  South America

    Brazil


  Middle East & Africa

    UAE


  Rest of World (ROW)

By Application Insights

The COPD segment is estimated to witness significant growth during the forecast period.

Chronic obstructive pulmonary disease (COPD) is a significant global health concern, being the fourth leading cause of death worldwide. With an estimated 12% of the global population affected, the prevalence and related healthcare costs are projected to increase in both developed and developing countries. The primary drivers of COPD include smoking and air pollution. Long-term oxygen therapy is the primary treatment for COPD patients with chronic respiratory failure, aiming to enhance their prognosis.

This market is influenced by various economic, political, and social scenarios. Macroeconomic analysis, value chain analysis, pricing analysis, and product development are crucial factors shaping the market's competitive position. External factors, such as regulations and positive/negative changes, also impact the market's growth trajectory. Understanding these elements is essential for businesses aiming to capitalize on opportunities and mitigate risks In the market.

Get a glance at the Venturi Mask Industry report of share of various segments Request Free Sample

The COPD segment was valued at USD 747.90 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 41% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America held a significant market share in 2023, with the US b

Introduction: Every year, millions of children die from preventable causes worldwide. According to World Health Organization, injuries are the leading cause of disability and death among all age groups below 60 years.Aim: This study aimed to evaluate the global research outcomes and trends, and some key bibliometric indicators in pediatric trauma.Methods: A descriptive bibliometric analysis study was designed. On June 14, 2021, an electronic search was performed in the Web of Science Core Collection database using the potential searching keywords “Pediatric AND Trauma” in the title field without any limitations. The search was performed using the Boolean search query method. The data were downloaded in plaintext and comma-separated values format. The required graphs were generated using OriginPro 2018. Furthermore, the data were transferred to HistCite™ software for bibliometric analysis. In addition, the obtained data were plotted for network visualization mapping using VOSviewer software version 1.6.15 for windows.Results: A total of 2,269 documents were included in the final analysis. The included documents were authored by 7,894 authors and published in 395 research and academic journals, mainly in the English language (n = 2,222). The main document types were articles (n = 1,276, citations = 18,244), and meeting abstracts (n = 331, citations = 19). Pediatric (n = 2,269) and trauma (n = 2,257) were the most widely used keywords. The most productive year was 2019 (n = 184, citations = 527). The most prolific author was Upperman JS (n = 29, citations = 202). The most attractive journals in pediatric trauma research were The Journal of Trauma and Acute Care Surgery (n = 290, citations = 5,199) and the Journal of Pediatric Surgery (n = 256, citations = 5,088). The most active institute was the University of California System (n = 110). The most dominant country was the United States of America (USA) (n = 1,620, citations = 22,983). The USA and Canada had the highest total link strength, 103 and 70, respectively.Conclusion: This study provides a comprehensive overview of research output in pediatric trauma. The USA continues to dominate scientific research and funding in pediatric trauma. Findings of the current study will help the researchers and clinicians to understand the recent achievements and research frontiers. Collaborative research initiative needs to be established between institutions in developed and developing countries and among researchers.